Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin Monotherapy in Progressive Malignant Pleural Mesothelioma
2017-001016-11Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in pleural mesothelioma, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression-free survival at 12 weeks. Started Jan 2021; status: completed.
02
Drugs
lurbinectedin
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2017-001016-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001016-11.